Brigatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and CHUIKYO (Japan), among others, recommended or restricted brigatinib, while CIPM (Spain) did not recommend it.
Assessment has run over 6.4 years, from 17 Dec 2018 at TLV (Sweden) to 7 May 2025 at CONITEC (Brazil).
TLV (Sweden) changed its position: restricted on 17 Dec 2018, recommended by 6 Jul 2020.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Against its own class, brigatinib is an outlier: 95% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
5 distinct indication wordings are recorded for brigatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 25 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess brigatinib, on 17 Dec 2018; CONITEC (Brazil) did not open a file until 7 May 2025 — a wide spread of 6.4 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
10 of the 14 agencies here assessed brigatinib more than once, AOTMIT (Poland) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
brigatinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for brigatinib reads 18 recommended, 3 restricted, 2 deferred to NICE and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 7 May 2025 | Tratamento de pacientes com câncer de pulmão não pequenas células com translocação em estágio localmente avançado ou met… | incorporated into SUS | source |
| DMC (Denmark) | 28 Apr 2021 | ALK-positiv ikke-småcellet lungekræft, 1. linjebehandling | Anbefalet | source |
| CHUIKYO (Japan) | 21 Apr 2021 | アルンブリグ錠３０ｍｇ | listed on the NHI price list · 89 days after PMDA approval | source |
| AOTMIT (Poland) | 19 Feb 2021 | Alunbrig reimbursement recommendation | recommended | source |
| NYE METODER (Norway) | 14 Feb 2021 | Førstelinjebehandling av ALK-positiv ikke-småcellet lungekreft. | introduced | source |
20 further decisions for brigatinib, across 12 agencies, are not shown here. They link to 18 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
Coverage: 25 decisions for brigatinib from 14 agencies, 2018 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.